TX-TANGO-NETWORKS
Tango Networks today announced Global Pass, a single rate subscription plan for Tango Extend across 39 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312069630/en/
Tango Extend Global Pass sets the new benchmark for global business mobile communications under a single subscription plan. (Photo: Business Wire)
The Tango Extend eSIM service already enables any subscriber’s smartphone to integrate directly with a company’s Unified Communications (UC) platform to provide remote employees, frontline, deskless and hybrid workers with seamless business communications.
Now, with Global Pass, Tango Extend subscribers enjoy a single fixed-rate business mobile service across 14 Home countries with seamless roaming in a further 25 Home Away countries across Europe and North America.
“Global Pass is a game-changer, enhancing the capabilities of Tango Extend to redefine how enterprises connect, communicate, and collaborate on a global basis,” said Lee Essex, Senior Vice President of Sales for Tango Networks. "With Global Pass, we empower enterprises to break free from traditional connectivity and geography constraints, fostering a new era of productivity and collaboration for the extended workforce."
Global Coverage with Borderless Roaming in 39 Countries
Global Pass liberates mobile communication from borders, enabling employees to stay connected effortlessly while traveling or working internationally.
Starting with 14 countries in the first half of 2024, Global Pass subscribers based in the USA, UK, Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Mexico, Luxembourg, Spain, Sweden, and Poland will be able to be resident or move freely between these countries and roam into 25 more countries across Europe and North America without the fear of incurring additional 'roaming' charges. Check coverage availability here: https://tango-networks.com/country-availability/
Later in 2024 and into 2025, Global Pass will expand to countries across Asia, Australasia, North and South America.
Seamless Integration for Mobile UC
Integrating with many leading UC platforms including Microsoft’s Teams Phone, Tango Extend enables workers to use their existing business numbers natively on their mobile phones, including Bring-Your-Own-Device (BYOD) mobile phones. Tango Extend provides a business e-SIM for any multi-SIM personal mobile phone. The eSIM is paid for and controlled by the business, allowing work communications and personal communications to be securely separated with dual personas. Business calls are made using the phone’s native dialer, rather than a mobile app.
Companies using Tango Extend are retiring landline desk phones, cutting expensive company-issued mobile phones, whilst at the same time reducing their carbon footprint and boosting worker productivity.
Incorporating groundbreaking fixed-mobile convergence technologies, Tango Extend is covered by more than 100 patents and has won more than 10 best new product and channel solution awards.
About Tango Networks:
Tango Networks is a pioneering force in providing cutting-edge mobile telecommunications solutions for enterprises globally. With a focus on innovation and customer-centricity, Tango Networks continues to revolutionize how businesses connect and communicate in a mobile-centric world.
Global Pass is available for immediate deployment, offering enterprises a transformative approach to mobile connectivity. For more details on Global Pass and Tango Networks' comprehensive suite of mobile telecommunications solutions, please visit tango-networks.com.
Tango Extend is a trademark of Tango Networks Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312069630/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom